Work

Faculty Opinions recommendation of SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.

Year: 2017

Type: peer-review

Source: Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature

DOI: 10.3410/f.727122838.793526980

Authors: Scott Kaufmann, Seongseok Yun

Institution: Mayo Clinic

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4241461325

Cites:

Cited by:

Related to: 10